Business
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
MOUNTAIN VIEW, Calif., December 02, 2025--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be prominently featured at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia where NeuroPace will feature new clinical and AI-driven advances that underscore the Company’s focus on delivering life-changing outcomes and enabling physicians to
About this update from Neuropace, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7c77926ec7065cf5c476a310bcf4a4a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yoBK19XZCGR9Fa1MRS81Iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7c77926ec7065cf5c476a310bcf4a4a6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IytJoVRCgkGJNbtHH0aAOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7c77926ec7065cf5c476a310bcf4a4a6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction--","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"--RNS® System to be featured in over 80 scientific presentations and posters, the most of any neuromodulation therapy--","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., December 02, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be prominently featured at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia where NeuroPace will feature new clinical and AI-driven advances that underscore the Company’s focus on delivering life-changing outcomes and enabling physicians to provide more confident, data-informed care for people living with epilepsy.","length":592,"tagName":"p"},{"type":"text","content":""Our presence at AES this year is about demonstrating life-changing, durable outcomes with the RNS System and how those outcomes are enabled by the depth and quality of our data," said Martha Morrell, MD, Chief Medical Officer at NeuroPace. "New analyses for the RNS System Post-Approval Study for focal epilepsy, together with emerging results from the NAUTILUS study for idiopathic generalized epilepsy, demonstrate that responsive neuromodulation can deliver meaningful and sustained seizure reductions for patients. At the same time, the intracranial EEG data recorded by the...